
|Articles|December 3, 2012
FDA approves cabozantinib to treat rare type of thyroid cancer
FDA has approved cabozantinib (Cometriq, Exelixis and AstraZeneca) for the treatment of progressive, metastatic medullary thyroid cancer (MTC).
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Pharmacists Remain Health Care Focal Point as Vaccine Recommendations Change
2
Diet and Insulin Management Technology Show Most Consistent Benefits for Type 1 Diabetes
3
Pharmacists Now Authorized to Independently Prescribe Buprenorphine
4
ACIP Vote Eliminates Universal Recommendation for Newborn Hepatitis B Vaccine
5



































































































































